Cencora, Inc. (NYSE:COR) Shares Acquired by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC lifted its position in shares of Cencora, Inc. (NYSE:COR) by 12.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,855 shares of the company’s stock after acquiring an additional 1,726 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Cencora were worth $3,572,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Cape Investment Advisory Inc. acquired a new position in shares of Cencora during the first quarter worth about $1,137,000. HM Payson & Co. acquired a new position in shares of Cencora during the first quarter worth about $708,000. Jackson Wealth Management LLC acquired a new position in shares of Cencora during the first quarter worth about $6,740,000. American Trust acquired a new position in shares of Cencora during the first quarter worth about $396,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in Cencora during the first quarter worth about $325,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the transaction, the insider now owns 24,418,171 shares of the company’s stock, valued at $5,252,836,945.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Gina Clark sold 27,093 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $216.07, for a total transaction of $5,853,984.51. Following the completion of the transaction, the executive vice president now owns 15,158 shares of the company’s stock, valued at $3,275,189.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now directly owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The disclosure for this sale can be found here. Insiders sold a total of 1,899,112 shares of company stock valued at $408,654,376 over the last 90 days. Insiders own 15.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR traded up $3.11 on Friday, hitting $247.57. The company’s stock had a trading volume of 3,292,432 shares, compared to its average volume of 1,217,035. Cencora, Inc. has a 12-month low of $171.65 and a 12-month high of $247.66. The company has a market capitalization of $49.38 billion, a price-to-earnings ratio of 27.09, a price-to-earnings-growth ratio of 1.68 and a beta of 0.45. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.53. The stock has a 50 day moving average of $228.85 and a 200-day moving average of $231.27.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.92 earnings per share. As a group, research analysts predict that Cencora, Inc. will post 13.56 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 26th. Stockholders of record on Friday, August 9th will be given a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date is Friday, August 9th. Cencora’s dividend payout ratio is presently 22.32%.

Analyst Ratings Changes

COR has been the topic of a number of research analyst reports. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday. SVB Leerink reissued an “outperform” rating and set a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. Wells Fargo & Company boosted their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday. Robert W. Baird boosted their price objective on shares of Cencora from $285.00 to $287.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Citigroup boosted their price objective on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $249.63.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.